Search, analyze & compare

My selected companies

Adjust valuation method
WatchlistNameTickerP/EP/SP/BEV/EbitdaROEROICRSISMA200DCFVolumeClosing price
-
Moderna IncMRNA-3.003.481.50-4.60-17.52%-15.14%36.01$43.94-$254.45125,978$45.65

Detail of Moderna Inc

 
CEO
Mr. Stephane Bancel
Employees
5600
Industry
Biotechnology
Sector
Healthcare
Market cap
$18B

Company details

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Revenue
Cost of goods
Gross profit
OE
R&D
G&A
OTH
OI
OIE
PI
TAX
NI
Revenue (Rev)
$5.06B
Cost of goods (CoG)
-$1.65B
Gross profit (GP)
$3.40B
Operating expense (OE)
-$6.10B
Research and development (R&D)
-$4.83B
General and administrative (G&A)
-$1.29B
Other (OTH)
$25.00M
Operating income (OI)
-$2.69B
Other income expense (OIE)
-$73.00M
Pretax income (PI)
-$2.35B
Tax (TAX)
$129.00M
Net income (NI)
-$2.22B
Moderna Inc
MRNA • XNGS • US
$45.65
-36.35 (-44.33%)
Stock vs Industry average
  • Industry average

Negative values are hidden from the graph.
Trailing annual dividend rate
$0.00
Payout ratio
0.00%
EPS
-$15.24
Margin profit
-43.77%
52 week low
$35.947899
52 week high
$166.610001
50-day simple moving average
$42.07
200-day simple moving average
$43.94
Percent held by insiders
9.52%
Percent held by institutions
71.58%
Dividend yield
0.00%

Change of shares

Cash vs Debt

Insider Trading

Comparison of selected companies

 
%
Price change
MRNA -44.33%
eps change
MRNA 0.00%